Thomson Medical Group expects loss for H1

This is primarily due to weaker performance in the Malaysia market.

Thomson Medical Group, together with its subsidiaries, has announced an expected after-tax loss for the six months ended 31 December 2024, based on a preliminary review of its unaudited financial results.

The anticipated loss is attributed primarily to weaker performance in the Malaysia market, which was impacted by the termination and discounting of certain insurance contracts. Additionally, higher interest expenses related to the acquisition of Far East Medical Vietnam Limited (FEMVN) and the cessation of certain projects in Singapore have contributed to the Group's financial challenges during the period.

TMG will release its unaudited financial results for the period on or before 14 February 2025.

Shareholders and investors are advised to exercise caution when trading TMG securities and to seek professional advice if needed.

Follow the link for more news on

Thomson Medical

Reaching the people who run Asia's businesses is harder than it used to be.

Inboxes are crowded. Attention is short. The executives you most want to reach — the founders, CFOs, and operators who actually move budgets — are the hardest to find through the usual channels. If you're building a company, a category, or a reputation, you already know this.

We've spent twenty years building the room they read. Singapore Business Review is where senior decision makers in Singapore and across Southeast Asia come for business coverage they can't get elsewhere — in print, online, and in person at the summits and roundtables we host across seven markets.

If you have something these readers should know about — a point of view worth publishing, a product worth their attention, an event worth their time — we'd like to hear what you're trying to do.

Book a meeting

| Or download the media kit (PDF)

240,000 senior readers quarterly in print Top 1,700 Singapore companies reached

7 markets across Southeast Asia